临床试验/NCT00634712

NCT00634712已完成3 期

Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity. Clinical Study of Candesartan in Patients With Heart Failure and Preserved Left Ventricular Systolic Function

AstraZeneca0 个研究点目标入组 734 人开始时间: 1999年6月最近更新: 2011年1月25日

适应症

干预措施

试验速览

阶段: 3 期
状态: 已完成
发起方: AstraZeneca
入组人数: 734
主要终点: Cardiovascular mortality or hospitalisation due to congestive heart failure

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者记录与标识符相似试验

研究概览

简要总结

A study to evaluate the effect of Atacand on patients with heart failure with preserved left ventricular function

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Parallel
主要目的: Treatment
盲法: Double

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Male or female aged 18 or above
•Congestive Heart Failure with symptoms for more than 4 weeks before starting study
•Provision of informed consent

排除标准

•Current low blood pressure with symptoms
•Liver disease considered significant by the study doctor
•Pregnant or lactating females

研究组 & 干预措施

1

Active Comparator

干预措施: Candesartan (Drug)

2

Placebo Comparator

干预措施: Placebo (Drug)

结局指标

主要结局

Cardiovascular mortality or hospitalisation due to congestive heart failure

时间窗: , 4, 6 weeks, 6 months, every 4 months thereafter until 24 months

次要结局

Cardiovascular mortality or hospitalisation for management of congestive heart failure, or non fatal MI(Cardiovascular mortality or hospitalisation for management of congestive heart failure, or non fatal MI)

研究者

发起方

AstraZeneca

申办方类型

Industry

相似试验

已完成

3 期

Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Added)Congestive Heart Failure

NCT00634309AstraZeneca597

已完成

3 期

Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)Congestive Heart Failure

NCT00634400AstraZeneca6,268

已完成

不适用

Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in FranceCohort StudyHeart Failure

NCT00679640AstraZeneca450

招募中

不适用

Study on the Correlation Between NAT2(N-acetyltransferase2) Gene Polymorphism and CrCl(Creatine Clreance) and the Efficacy and Safety of Levosimendan in Patients With Severe Heart FailureLevosimendanHeart FailureEfficacySafety

NCT05913271Yi Han352

Unknown

3 期

Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive PatientsCardiovascular DiseasesHypertension

NCT00125463The Japanese Society of Hypertension3,200